FDAClass IIAugust 13, 2025

Recombinate recall: CGMP Deviations

RECOMBINATE, [Antihemophilic Factor (Recombinant)], 5 mL vials, Rx Only, Takeda Pharmaceuticals USA, Cambridge, MA 02142, NDC: 00944-2843-01

Why was Recombinate recalled?

CGMP Deviations - Product was exposed to temperatures outside the product's labeled storage requirements.

What should I do if I have this product?

The recall is ongoing. Follow the firm and FDA instructions.

What to do with a recalled product: refunds, receipts, safe disposal and how to report a problem.

Is my product affected?

Compare the item in your hand with every identifier below from the official FDA record. Only products that match the listed product and lot, UPC or model codes are part of this recall.

Which lot codes, UPCs or models are affected?

Lot: TRB23802AC, Expires: 03/18/2026; TRA22804AA, Expires: 10/18/2025

Product
RECOMBINATE, [Antihemophilic Factor (Recombinant)], 5 mL vials, Rx Only, Takeda Pharmaceuticals USA, Cambridge, MA 02142, NDC: 00944-2843-01
Recalling firm
Cardinal Health Inc.
Quantity
3 units
Distribution
Nationwide Within the U.S.
Recall date
August 13, 2025
Classification
Class II
Status
Ongoing
Agency
FDA (drug)
Open FDA enforcement record Latest recalls